Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding

Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last month ceased its cancer R&D and announced it would explore strategic alternatives. The post Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3…

Read More

KFF Health News’ ‘What the Health?’: Live From Aspen — Governors and an HHS Secretary Sound Off

The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…

Read More

What Could the Health-Related Provisions in the Reconciliation Bill Mean for Older Adults?

The Trump Administration and Congress are moving quickly to pass legislation that could have significant implications for health coverage of older Americans. The House-passed reconciliation bill awaiting action by the full Senate, known as the One Big Beautiful Bill, includes several provisions that would affect health insurance coverage and well-being of older adults ages 50…

Read More

Shifts in Funding Priorities and Vaccine Guidance Contribute to Safety Myths, Plus Reactions to Ruling in U.S. v. Skrmetti — The Monitor

This volume examines how the cancellation of contracts to develop a bird flu vaccine and unfounded claims by new vaccine advisors reflect persistent myths about the safety of mRNA technology. It also explores false claims linking COVID-19 vaccines to miscarriage and analyzes how reactions to a Supreme Court ruling on gender-affirming care for minors highlights…

Read More